Perceptive Advisors’s Galmed Pharmaceuticals GLMD Stock Holding History

Perceptive Advisors’s Portfolio GLMD Stock Details GLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-417	Closed	-$369K	–	186
2016 Q1	$369K	Hold	417	–	–	0.03%	138
2015 Q4	$571K	Hold	417	–	–	0.04%	99
2015 Q3	$557K	Hold	417	–	–	0.04%	109
2015 Q2	$755K	Hold	417	–	–	0.05%	124
2015 Q1	$706K	Hold	417	–	–	0.05%	110
2014 Q4	$435K	Hold	417	–	–	0.04%	115
2014 Q3	$645K	Hold	417	–	–	0.07%	89
2014 Q2	$731K	Hold	417	–	–	0.07%	84
2014 Q1	$860K	Buy	+417	New	+$977K	0.09%	89

Other funds holding GLMD

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

SKK

Shepherd Kaplan Krochuk Boston, Massachusetts $119M AUM 8.32% 1-Year Est. Return

CAD

Craig A. Drill $24.4M AUM 13.42% 1-Year Est. Return

Menta Capital San Francisco, California $236M AUM 6.6% 1-Year Est. Return

CapWealth Advisors Franklin, Tennessee $1.35B AUM 34.16% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

WJA

Williams Jones & Associates New York $4.82B AUM 19.95% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Perceptive Advisors's GLMD Position: Q2 2016 in Review

Perceptive Advisors sold out of Galmed Pharmaceuticals (GLMD) in Q2 2016, closing a stake of 417 shares — an estimated $369K sold.

Perceptive Advisors first reported a position in GLMD in Q1 2014 and held it in 9 quarters. The position peaked at $860K in Q1 2014. 17 funds tracked by Wall St. Rank hold GLMD as of Q2 2016.

Perceptive Advisors reported no remaining Galmed Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Perceptive Advisors sold 417 Galmed Pharmaceuticals shares in Q2 2016, an estimated $369K.
Perceptive Advisors first reported a position in Galmed Pharmaceuticals in Q1 2014 and held it in 9 quarters.
Perceptive Advisors's Galmed Pharmaceuticals position peaked at $860K in Q1 2014.
17 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q2 2016.

Based on Perceptive Advisors's 13F filing for Q2 2016, filed 11 Aug 2016.